Title:
CELLS EXPRESSING FAS LIGAND AND CFLIP POLYPEPTIDES AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/122234
Kind Code:
A3
Abstract:
The presently disclosed subject matter provides cells comprising a Fas ligand (FasL) polypeptide and a cFLIP polypeptide. In certain embodiments, the cells further comprise an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR), or a TCR like fusion molecule). Also provided are uses of the cells for cell lysis of target cells expressing Fas, and for treating diseases or disorders, e.g., tumors.
More Like This:
| WO/2003/068959 | NOVEL SCREENING METHOD |
| WO/2020/166592 | HEMIASTERLIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF |
| WO/2021/232057 | METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE |
Inventors:
ADUSUMILLI PRASAD (US)
SADELAIN MICHEL (US)
CHEN NAN (US)
CHINTALA NAVIN (US)
PERICA KARLO (US)
SADELAIN MICHEL (US)
CHEN NAN (US)
CHINTALA NAVIN (US)
PERICA KARLO (US)
Application Number:
PCT/US2022/053749
Publication Date:
August 10, 2023
Filing Date:
December 22, 2022
Export Citation:
Assignee:
MEMORIAL SLOAN KETTERING CANCER CENTER (US)
SLOAN KETTERING INST CANCER RES (US)
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US)
SLOAN KETTERING INST CANCER RES (US)
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US)
International Classes:
A61K39/395; A61K38/17; A61P35/00; A61P37/02; C07K19/00
Foreign References:
| AU782255B2 | 2005-07-14 | |||
| US6951919B1 | 2005-10-04 | |||
| US20020052474A1 | 2002-05-02 | |||
| US20210128721A1 | 2021-05-06 | |||
| US20180273601A1 | 2018-09-27 |
Attorney, Agent or Firm:
LENDARIS, Steven, P. et al. (US)
Download PDF: